Blue Bell, Pennsylvania, March 24, 2021 – IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, would like to congratulate Spirovant Sciences, Inc. for expanding its headquarters and laboratories by adding new research and development space in the robust gene and cell therapy epicenter of Philadelphia’s University City at 3675 Market Street.
The facility will support Spirovant’s ongoing gene therapy research into treatments for cystic fibrosis, a life-threatening disease that affects thousands of people worldwide. Given the urgency of Spirovant’s work in gene therapy to develop treatments and cures for respiratory diseases, the fast-track execution provides an anticipated move in date to the labs facilties in the summer of 2021.
After careful consideration of multiple properties within University City, Spirovant decided on Wexford Science + Technology’s uCity Square because of the vibrant ecosystem of life sciences companies and the ability to expand incrementally within the same building. It is also in an ideal part of the city to find great talent. It is surrounded by colleges and universities, research institutions, and world-renowned hospitals working in the cell and gene therapy space.
“We are really happy for the Spirovant team,” states Tom Piombino, Vice President and Biotechnology/CGT Process Architect at IPS. “They are an inspiring group of people and we’re thankful to have been selected to assist them in finding a great home in University City, a place that they love, pursuing the science that they are incredibly passionate about.”
IPS is providing a portfolio of project delivery services from programming, engineering and design, construction management, and procurement through facility start-up.
Download this full announcement here.